SCHEMBL894205

SCHEMBL894205

OC[C@@H]1Cc2ccccc2CN1

nearest known ligand 0.69

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PNMT P11086 8/20 0.67
ADRA2A P08913 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29590036 1.00 PNMT (0.67) PNMTADRA2A
SCHEMBL29570471 1.00 PNMT (0.67) PNMTADRA2A
SCHEMBL29743356 1.00 PNMT (0.67) PNMTADRA2A
SCHEMBL894207 1.00 PNMT (0.67) PNMTADRA2A
SCHEMBL4738129 1.00 PNMT (0.67) PNMTADRA2A
Hydrochloric Acid SCHEMBL7478887 0.98 PNMT (0.65) PNMTADRA2A
Hydrochloric Acid SCHEMBL7478882 0.98 PNMT (0.65) PNMTADRA2A
SCHEMBL8783405 0.85 PNMT (0.64) PNMT
SCHEMBL11388285 0.85 PNMT (0.64) PNMT
SCHEMBL8853554 0.83 PNMT (0.71) PNMTADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117586170-B Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative 江苏集萃分子工程研究院有限公司 2024-04-09 CN claimed
CN-117586170-A Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative 江苏集萃分子工程研究院有限公司 2024-02-23 CN claimed
US-20250387504-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2025-12-25 US disclosed
WO-2025111450-A1 ANTI-CD74 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF LES LABORATOIRES SERVIER (FR) 2025-05-30 WO disclosed
WO-2025111431-A1 ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF LES LABORATOIRES SERVIER (FR) 2025-05-30 WO disclosed
EP-4525927-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF Novartis AG (CH) 2025-03-26 EP disclosed
WO-2025032556-A1 BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF BEIGENE SWITZERLAND GMBH (CH) 2025-02-13 WO disclosed
WO-2025032555-A1 BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF BEIGENE SWITZERLAND GMBH (CH) 2025-02-13 WO disclosed
EP-4482832-A1 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-Y L]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS Les Laboratoires Servier (FR) 2025-01-01 EP disclosed
US-20240245699-A1 PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2024-07-25 US disclosed
US-20240197898-A1 SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS IMMUNOGEN, INC. 2024-06-20 US disclosed
EP-0914332-B1 ISOQUINOLINES USEFUL AS ANALGESICS ASTRAZENECA AB (SE) 2002-05-08 EP disclosed
EP-1149079-A1 TETRAHYDRO ISOQUINO LINEALKANOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SK Corporation (KR) 2001-10-31 EP disclosed
WO-2000046204-A1 TETRAHYDRO ISOQUINO LINEALKANOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SK CORPORATION (KR) 2000-08-10 WO disclosed
US-6034097-A Isoquinolines useful as analgesics ASTRA AB (SE) 2000-03-07 US disclosed
US-5955471-A USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, INCLUDING DEPRESSION SK CORPORATION (US) 1999-09-21 US disclosed
US-4189480-A ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC RHONE-POULENC INDUSTRIES (FR) 1980-02-19 US disclosed
US-4153698-A ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC RHONE-POULENC INDUSTRIES (FR) 1979-05-08 US disclosed
US-4108999-A ANTIULCER AGENTS RHONE-POULENC INDUSTRIES (FR) 1978-08-22 US disclosed
US-4064247-A ANALGESIC, ANTIPYRETIC RHONE-POULENC INDUSTRIES (FR) 1977-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250387504-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF BID, BCL2, MCL1 PNMT 3562/4885ADRA2A 4283/4885
US-20240197898-A1 SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS MKI67, GABBR1, GABBR2 PNMT 1170/4885ADRA2A 371/4885
US-20240245699-A1 PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PDCD11, RRM2B, RRM2 PNMT 3109/4885ADRA2A 1292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.